吉非替尼对EGFR突变晚期非小细胞肺癌患者肿瘤标志物及循环血miR的影响  

Effect of Gefitinib on Tumor Markers and Circulating Blood miR in Patients with Advanced Non-small Cell Lung Cancer with EGFR Mutation

作　　者：黄素芳 黄秋玲 吴佩凤 刘利敏 HUANG Sufang;HUANG Qiuling;WU Peifeng;LIU Limin

机构地区：[1]联勤保障部队第910医院药剂科,福建泉州362000

出　　处：《中国医学创新》2024年第35期119-123,共5页Medical Innovation of China

基　　金：2013年福建省卫生系统中青年骨干人才培养项目(2013-ZQN-JC-14)。

摘　　要：目的:探究吉非替尼对表皮生长因子受体(EGFR)突变晚期非小细胞肺癌患者肿瘤标志物及循环血微小RNA(miR)的影响。方法:将2021年12月—2023年10月联勤保障部队第910医院收治的80例EGFR突变晚期非小细胞肺癌患者根据随机数字表法分为对照组(n=40)和观察组(n=40)。对照组采用多西他赛进行治疗,观察组则采用吉非替尼进行治疗。比较两组治疗总缓解率、各类毒副反应发生率、治疗前后疾病相关血液指标[人表皮生长因子受体2(HER2)、EGFR]、肿瘤标志物[癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)及细胞角蛋白19片段(Cyfra21-1)]及循环血miR指标(miR-155、miR-21及miR-34a)。结果:观察组治疗总缓解率显著高于对照组,各类毒副反应发生率均显著低于对照组,差异均有统计学意义(P<0.05)。治疗前两组疾病相关血液指标、肿瘤标志物及循环血miR指标比较,差异均无统计学意义(P>0.05);治疗后观察组疾病相关血液指标、肿瘤标志物及循环血miR指标均显著低于对照组,差异均有统计学意义(P<0.05)。结论:吉非替尼在EGFR突变晚期非小细胞肺癌患者中的应用效果较好,安全性较高,可显著改善肿瘤标志物及循环血miR的表达。Objective:To investigate the the effects of Gefitinib on tumor markers and circulating blood microRNA(miR)in patients with advanced non-small cell lung cancer with epidermal growth factor receptor(EGFR)mutation.Method:A total of 80 patients with advanced non-small cell lung cancer with EGFR mutation admitted to 910th Hospital of Joint Logistics Support Force from December 2021 to October 2023 were divided into control group(n=40)and observation group(n=40)according to random number table method.The control group was treated with Docetaxel,and the observation group was treated with Gefitinib.The total remission rate of treatment,incidence of various toxic and side effects,disease-related blood indexes[human epidermal growth factor receptor 2(HER2),EGFR],tumor markers[carcinoembryonic antigen(CEA),neuron specific enolase(NSE)and cytokeratin 19 fragment(Cyfra21-1)]and circulating blood miR indexes(miR-155,miR-21 and miR-34a)before and after treatment were compared between the two groups.Result:The total remission rate of treatment in the observation group was significantly higher than that in the control group,and the incidence of various toxic and side effects were significantly lower than those in the control group,the differences were statistically significant(P<0.05).There were no significant differences in disease-related blood indexes,tumor markers and circulating blood miR indexes between the two groups before treatment(P>0.05).After treatment,disease-related blood indexes,tumor markers and circulating blood miR indexes in the observation group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:The application of Gefitinib in patients with advanced non-small cell lung cancer with EGFR mutation has good effect and high safety,and can significantly improve the expression of tumor markers and circulating blood miR.

关 键 词：吉非替尼 EGFR突变 晚期非小细胞肺癌 肿瘤标志物 循环血miR 

分 类 号：R734.2[医药卫生—肿瘤]